fashion -WSS

fashion

author：leisure time 2025-08-19 20:47:34 - browse：8

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： 5 important ways Henrietta Lacks changed medical science

WSS

The public health thinking behind the CDC’s new Covid guidance

IVF doctors demand details after CooperSurgical lawsuit

Florida health officials providing scant details on measles cases

Breakthrough Alzheimer’s drugs are inaccessible in rural states

‘Oppenheimer’ and the risks of AI in health care

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

focus

fashion

focus

Hollywood unions extend contract negotiations for actors

Amazon expands telehealth clinic nationwide

Novavax promises a turnaround & Lilly roils the obesity market

What the US credit downgrade means for the economy, your finances

Medicare details structure of new drug price negotiation program

Lack of health data on LGBTQ+ people has serious consequences

Medicare proposal to cover medical devices draws a mixed reaction

Lack of health data on LGBTQ+ people has serious consequences

Supreme Court strikes down use of affirmative action

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

hotspot

Sage hopes for a blockbuster in antidepressant now before FDA

What the US credit downgrade means for the economy, your finances

NIH launches clinical trials and new research office for long Covid

What the airline industry can learn from medicine

The high personal cost of affirmative action for Black doctors

Why Talkspace is targeting Medicare, a tricky market

hotspot

Wikipedia

Wikipedia

leisure time